The 5 Big Takeaways From Our House Forecast Aug. 17,

New Post Public Reply Private Reply Replies (1) Message Board

Aug 17, 2018 at 10:09 AM 210

Quote:

The 5 Big Takeaways From Our House Forecast

Aug. 17, 2018, at 7:24 AM

By Nate Silver

https://fivethirtyeight.com/wp-content/upload...&ssl=1

Theme No. 1: A broad consensus of indicators point toward Democrats performing well

In contrast to our presidential forecasts, which are heavily dependent on polling, our House model uses a broad mix of polling and non-polling indicators, including factors such as fundraising totals and historical trends in midterms. Those indicators look both pretty good for Democrats and remarkably consistent with one another:

◾The Lite version of our forecast, which focuses as much as possible on district-level and generic ballot polls, projects Democrats to win the popular vote for the House by 7 or 8 percentage points.
◾The Classic version of the model, which incorporates a lot of non-polling metrics such as fundraising and past voting in each district, also shows Democrats winning the popular vote by 7 or 8 points.
◾The generic ballot, which influences all three versions of our forecast, has generally shown Democrats with a lead of … 7 to 8 percentage points.
◾And finally, our model calculates a starting assumption about the race based on historical trends in midterms since 1946 and presidential approval ratings. It also implies that Democrats “should” win the House popular vote by about 8 percentage points — just what the other metrics show.

So you’d expect Democrats to do pretty well based on the historical propensity of opposition parties to gain ground in midterm elections, especially under unpopular presidents. And Democrats are doing roughly as well as you’d expect them to according to most indicators of the national environment.

There are a couple of exceptions — indicators that are a little out of the consensus — but both of them fall on the better-for-Democrats side of the consensus. First, Democrats have done really impressively in fundraising.

Their candidates have raised more in individual contributions than Republicans in 71 of the 101 districts rated as competitive by the Cook Political Report, despite the fact that about two-thirds of these districts feature Republican incumbents. That’s unusual. Most challengers significantly trail in fundraising at this point in the cycle.

Meanwhile, the results of special elections have been very good for Democrats. Our model doesn’t actually use special election results in its forecasts, but they’re part of a coherent alternative narrative in which there’s upside for Democrats relative to what our forecast shows.

Donating money and voting in special elections are tangible indicators of voter engagement, and it’s possible that they point toward a Democratic enthusiasm advantage that could become clearer later on in the cycle.

Theme No. 4: Potential Democratic gains are broad-based, across all regions of the country

One factor helping Trump in 2016 was that he really needed to beat his polls in only one part of the country, the Midwest, to defeat Hillary Clinton in the Electoral College. (Outside of the Midwest, the polls were reasonably accurate and even underestimated Clinton in some states.) By contrast, Republicans are facing a multi-front assault in the House this year:

◾In the Northeast, they have a lot of exposure in New York and New Jersey, which were once bastions of moderate Republicanism but which have become increasingly inhospitable to it — and in Pennsylvania, where court-ordered redistricting resulted in a bad map for Republicans and where a lot of GOP incumbents have retired.
◾In the South, they face pressure because of demographic change in states such as Georgia and Virginia — and increasingly in Texas.
◾In the Midwest, there’s the risk of reversion to the mean with Trump off the ballot, especially as the GOP coalition in these states has come to rely on non-college voters who don’t always participate in midterm elections.
◾And in the West, there are 14 Republican incumbents in California and another four in Washington who are increasingly running against the political current as the Pacific Coast becomes a somewhat literal “blue wall”.

As it happens, projected Democratic gains are almost evenly distributed between the four Census Bureau regions: The Classic version of our model projects them to gain nine seats in the Midwest, nine in the South, nine in the Northeast, and nine in the West. Note that Democrats could completely flop in any one of these regions and yet still (just barely) win enough seats to take the House.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...